TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments.
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
OriginClear Licenses Technology to Water Technologies International, Inc. (WTII) for Southeastern USA
OriginClear’s investment in WTII also helps close a strategic acquisition Los Angeles, CA – June 12, 2018 – OriginClear Inc . (OTC/QB: OCLN ), a leading provider of water treatment solutions, recently entered into a licensing agreement with Water Technologies International, Inc. (OTC: WTII ), of Port St. Lucie, FL, which commericializes the innovative SIMPOD…Details
Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of…Details
Water Technologies International, Inc. Utilizing OriginClear’s Technologies To Pave New Roads
History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
FISION Granted Second U.S. Patent for Cloud-based Marketing Technology
JACKSONVILLE, Florida, May 31, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City. TapImmune Company Presentation Date : Thursday, June 7, 2018 Time : 3:30 PM…Details
JACKSONVILLE, Florida, May 30, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel. Immuno-Oncology…Details